Radically resected pancreatic cancer and adjuvant treatment. A review of the literature
| Autor: | Fabrizio, Drudi, Davide, Tassinari, Jacopo, Giuliani, Claudio, Ridolfi, Lorenzo, Gianni, Emiliano, Tamburini, Manuela, Fantini, Carlotta, Santelmo, Eleonora, Barzotti, Nadia, Lotti, Alberto, Ravaioli |
|---|---|
| Přispěvatelé: | F. Drudi, D. Tassinari, J. Giuliani, C. Ridolfi, L. Gianni, E. Tamburini, M. Fantini, C. SantelmoE. Barzotti, N. Lotti |
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Antimetabolites
Antineoplastic randomized clinical trials Mitomycin pancreatic cancer Adjuvant treatment chemotherapy Combined Modality Therapy Deoxycytidine Survival Analysis Gemcitabine Disease-Free Survival chemoradiotherapy Pancreatic Neoplasms Clinical Trials Phase II as Topic Pancreatectomy Clinical Trials Phase III as Topic Chemotherapy Adjuvant Doxorubicin Antineoplastic Combined Chemotherapy Protocols Practice Guidelines as Topic Humans Multicenter Studies as Topic Radiotherapy Adjuvant Fluorouracil Randomized Controlled Trials as Topic |
| Popis: | Adjuvant therapy represents the gold standard treatment for radically resected pancreatic cancer. Results from randomized clinical trials confirmed the efficacy of adjuvant therapy for pancreatic cancer but did not define what is the "right choice" in terms of type of antiblastic drug (among gemcitabine, 5-fluorouracil or other drugs), role of polychemotherapy and chemoradiotherapy. The objective of our study was to evaluate the efficacy and toxicity of adjuvant chemotherapy and chemoradiotherapy for radically resected pancreatic cancer through a systematic review of literature data, emphasizing the benefits regarding overall survival, disease-free survival and toxicity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|